3 October 2024 F2G’s September $100m funding round provides the company with crucial funds to
renavigate approval of its lead drug, olorofim. The substantial financing also
highlights the paucity of novel antifungal products in the clinic.
Italian pharma major Recordati saw its shares rise more than 5% to 52.00 euros in early trading, as it announced a deal to expand its portfolio of marketed rare disease medicines. 4 October 2024
Paris-based asset manager Kurma Partners has raised 140 million euros ($154 million), successfully completing the first closing of Biofund IV 4 October 2024
Bristol Myers Squibb has received a new approval from the US Food and Drug Administration for its blockbuster checkpoint blocker, Opdivo (nivolumab). 4 October 2024
Singapore’s Agency for Science, Technology and Research (A*STAR) and US biotech incubator Flagship Pioneering have agree to collaborate on advancing health and sustainability outcomes in Singapore and the broader Asia Pacific region. 4 October 2024
The US Food and Drug Administration (FDA) has removed the partial clinical hold on delpacibart etedesiran (del-desiran/AOC 1001), an investigational treatment designed to address the root cause of myotonic dystrophy type 1 (DM1), under development by US biotech Avidity Biosciences . 4 October 2024
The US Food and Drug Administration (FDA) has granted the Gilead Sciences subsidiary Kite a Regenerative Medicine Advanced Therapy Designation (RMAT) for Yescarta (axicabtagene ciloleucel) for adults with newly-diagnosed, high-risk large B-cell lymphoma (LBCL). 3 October 2024
Kedrion Biopharma has finalized an agreement with Germany-based Biotest for the long-term commercialization and distribution of Yimmugo (immune globulin) in the USA. 3 October 2024
US clinical-stage biotech Arcus Biosciences has entered into a clinical trial collaboration with AstraZeneca on renal cancer treatments. 3 October 2024
PeptiDream says that its wholly-owned PDRadiopharma subsidiary has entered into a strategic partnership with French nuclear medicines firm Curium. 3 October 2024
Privately-held Ferring Pharmaceuticals has announced the opening of a global manufacturing hub in Finland for the drug substance of its intravesical non-replicating gene therapy Adstiladrin (nadofaragene firadenovec-vncg). 3 October 2024
Shares of UK drug developer Hemogenyx Pharmaceuticals rose as much as 9% and closed up 5.9% at 1.70 pence yesterday on the news of a further investment from Prevail Partners. 3 October 2024
UK-based biotech Resolution Therapeutics has announced the completion of a £63.5 million ($76.8 million) series B financing round led by Syncona. 3 October 2024
The BioIndustry Association (BIA), in collaboration with the Centre for Process Innovation (CPI), has published a new report on the UK’s mRNA sector. 2 October 2024
Aspen Neuroscience, a private biotechnology company specializing in autologous cell therapies, has announced the opening of a major new facility near its headquarters in San Diego. 2 October 2024
Privately-held UK biotech Curve Therapeutics today announced the further strengthening of its leadership team with the appointments of Andre Hoekema as chairman of the board and Cora Griffin as head of business development. 2 October 2024
NK:IO, a London startup developing a cell therapy for treating solid tumors, has announced the appointment of a permant chief executive and the finalization of a seed funding round. 2 October 2024
Californian start-up Caribou Biosciences (Nasdaq: CRBU) has announced significant workforce reductions, cutting approximately 12% of its staff. 19 July 2024
Swedish firm Enzymatica (STO: ENZY) will conduct a rights issue to raise approximately $12 million, with existing shareholders being given preferential rights. 18 July 2024
The show is over for Aslan Pharmaceuticals, the immunology-focused biopharmaceutical company, as its financial troubles have led it to file for voluntary liquidation. 18 July 2024
French pharma major Sanofi announced that full results from the XTEND-Kids Phase III study have been published in The New England Journal of Medicine (NEJM). 18 July 2024
Basel, Switzerland-based Roche has announced promising new, four-year data from the RHONE-X extension study, the largest long-term study on diabetic macular edema (DME). 18 July 2024
Relay Therapeutics in a Securities and Exchange Commission (SEC) filing that it has received notice of termination of the collaboration and license agreement with Genentech 17 July 2024
SOTIO Biotech, a Czech biopharma owned by PPF Group, and Biocytogen, a Chinese firm focused on the discovery of novel antibody therapeutics, have announced a research collaboration and exclusive option and license agreement. 16 July 2024
Cardurion Pharmaceuticals, which is developing next-generation therapeutics for the treatment of cardiovascular diseases, today announced a $260 million Series B financing. 16 July 2024
AbbVie’s market leadership, driven by its flagship disease-modifying antirheumatic drug Humira (adalimumab), faced a significant test with the 2023 loss of patent protection. 16 July 2024
German oncology start-up CatalYm has secured $150 million in a series D financing round to expand the development of its therapy, visugromab. 16 July 2024
Nucleome Therapeutics, a UK biotech using spatial genomics to discover precision medicines for complex diseases, has appointed Mark Bodmer as chief executive. 16 July 2024
Switzerland-based Asceneuron, a biotech developing small molecules targeting tau protein aggregation, a root cause of neurodegenerative disease, has announced a $100 million oversubscribed Series C financing. 16 July 2024
Shares in Legend Biotech (Nasdaq: LEGN) have climbed around 15% in recent days, after reports that the company has received a takeover offer. 15 July 2024
Sign up to receive email updates Join industry leaders for a daily roundup of biotech & pharma news
Company Spotlight
A pre-clinical stage biopharmaceutical group developing new medicines and treatments to treat blood and autoimmune disease and to bring the curative power of bone marrow transplantation to a greater number of patients suffering from otherwise incurable life-threatening diseases.